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Therapeutic K6a siRNA
K6a is the most common keratin gene 
mutated in pachyonychia congenita 
(PC). Smith and colleagues developed 
RNAi potent against K6a as a model 
for treating localized dominant skin 
disorders such as PC. Using transient 
transfection of each of the four K6a 
siRNAs, they demonstrated near-com-
plete ablation of endogenous K6a 
protein expression in two keratinocyte 
cell lines. In live mice, K6a-specific 
siRNA strongly inhibited bicistronic 
K6a luciferase gene expression. These 
data suggest that siRNAs can target mutated genes in the skin and support the devel-
opment of these inhibitors as potential therapeutics. See page 50
Melanosome Secretory Pathway
Early-stage melanosomes must remain 
anchored in the perinuclear area to receive 
melanosomal proteins critical to matura-
tion and eventual pigment biosynthesis. 
Watabe et al. characterized the process-
ing of the melanosomal proteins TYR and 
Pmel17 in early and late steps of the secre-
tory pathway, respectively, and investigated 
the mechanisms underlying the subcellular 
localization and transport of early melano-
somes. They report that early melanosome 
movement depends primarily on micro-
tubules but not actin filaments. In contrast, 
TYR and Pmel17 trafficking depends on 
cytoplasmic dynein and its interaction with the spectrin/ankyrin system involved in 
sorting plasma membrane cargo. See page 162
Hapten-Induced Murine Model for Atopic Dermatitis
Man and colleagues used a mouse model of 
hapten-induced allergic contact dermatitis 
to study the pathogenesis of atopic dermati-
tis (AD) and to assess alternative therapeutic 
approaches. After 9–10 hapten challenges 
to oxazolone-sensitized mice over a 2- to 3-
week period, this model shifted from typical 
delayed-type hypersensitivity reactions to a 
more chronic dermatosis with important fea-
tures of AD. Because of its reproducibility, 
predictability, and low cost, this model could 
prove useful for evaluating both pathogenic 
mechanisms and potential therapies for AD. 
See page 79
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Medication Risk for 
SCAR
To evaluate medications’ risk 
of inducing severe cutaneous 
adverse reactions (SCARs), 
Mockenhaupt and colleagues 
conducted a multinational case–
control study i n Europe between 
1997 and 2001. The study involved 
379 SCAR cases and 1,505 
controls. Among drugs recently 
introduced to the market, strong 
associations were documented 
for nevirapine and lamotrigine, 
with weaker associations 
for sertraline, pantoprazole, 
and tramadol. Strong 
associations were confirmed 
for anti-infective sulfonamides, 
allopurinol, carbamazapine, 
phenobarbital, phenytoin, and 
oxicam–NSAIDs. See page 35
SEER Predicts 
Melanoma 
Heterogeneity
Lachiewicz and colleagues 
examined 48,673 cases in the 
National Cancer Institute’s 
Surveillance, Epidemiology, and 
End Results (SEER) program 
and reported that divergent 
age-specific incidence patterns 
separated by sex and site 
revealed distinct melanoma 
subgroups, supporting 
theories that melanoma is a 
heterogeneous cancer, likely to 
represent tumors with multiple 
etiologies and possibly different 
outcomes. The research 
demonstrates the value of 
using a large-scale, population-
based database for hypothesis 
generating and testing. Further 
research on the genetic 
makeup of distinct phenotypes 
may improve the ability to 
prevent and treat melanoma. 
See page 243 
